Potted especially likes the following key paragraph from the Zacks Highlights . . . "But the main thing we like about Isis is that the company is extremely well capitalized. Isis should exit 2008 with over $450 million in cash. Management should be able to raise another $190 million in 2009 by selling its Ibis biosensor business to Abbott Labs (NYSE: ABT - News). That puts the company in an exceptionally solid financial situation to go along with the solid drug discovery / development fundamentals. Add the two together and you can see why it’s our top-pick right now."
Well . . . ISIS is Potted's TOP PICK too! ( sorry to disappoint the Alnylam Dream Team, but Potted invests in technologies that WORK! )